PLIANT THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M |
| Research and development | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M |
| Operating expenses | $156.4M | $228.4M | $185.7M | $136.9M | $105.1M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M |
| Interest expense | $2.6M | $3.0M | $1.3M | $791,000 | $0 |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M |
| Balance Sheet | |||||
| Cash and equivalents | $45.4M | $71.2M | $63.2M | $33.7M | $51.7M |
| Current assets | $196.4M | $362.3M | $505.5M | $340.3M | $209.4M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M |
| Current liabilities | $16.4M | $33.2M | $28.5M | $23.9M | $16.8M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M |
| Total debt | — | $30.0M | $10.0M | $10.0M | $0 |
| Stockholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
| Cash Flow Statement | |||||
| Cash from operations | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M |
| Depreciation and amortization | $1.7M | $2.1M | $1.8M | $1.8M | $1.5M |
| Stock-based compensation | $26.2M | $37.6M | $44.5M | $22.6M | $10.4M |
| Capital expenditure | $374,000 | $3.8M | $921,000 | $1.8M | $2.0M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M |
Shares outstanding 61.9M · Free float 78.3%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.